I received my PhD with Cum Laude from the Netherlands Cancer Institute, defining a novel mode of action of a broadly used anti-cancer drug, doxorubicin, and its anthracycline members. I discovered that doxorubicin and other anthracycline members can also destabilize nucleosomes and evict histones from particular chromatin regions upon intercalating into the chromatin. As a result, DNA damage response is attenuated and the epigenome of the cell is deregulated. After brief period of post-doc training at the Netherlands Cancer Institute, I moved to the Department of Genetics, Stanford University in the US, where I developed unique genome-wide screen systems to study the function of the non-coding genome. In 2018 I started my research group at the Department of Cell and Chemical Biology. I was awarded the Antoni van Leeuwenhoek Prize from NKI-AvL, the Academic Excellence Award from China, Gisela Thier Fellowship, and KWF/Alpe Young lnvestigator Grant.
Systematic identification of silencers in human cells.
Pang B., Snyder MP.
Nature Genetics. 2020, Feb24
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.
Pang B.*, Qiao X.*, Janssen L., Velds A., Groothuis T., Kerkhoven R., Nieuwland M., Ovaa H., Rottenberg S., van Tellingen O., Janssen J., Huijgens P., Zwart W. and Neefjes J.
Nature Communications. 2013;4:1908
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Pang B.*†, de Jong J.*, Qiao X.*, Wessels L.F.A.†, Neefjes J.†.
Nature Chemical Biology. 2015, 11, 472–480.